

**Cancer Australia - Contract Listings - Grants**  
**Reporting Period - Calendar Year - 2020**

Grant Participant / Supplier	Description	Commencement Date	Completion Date	Value (GST incl)	Confidentiality provision Y/N	Contract Ref
Austin Health/Olivia Newton-John Cancer Centre	Supporting people with cancer Grant initiative:Optimising the engagement of Culturally and Linguistically Diverse cancer patients and their families with supportive care designed to improve wellness.	5/04/2018	30/03/2021	\$130,705.30	N	CA 1718 172
Australia and New Zealand Breast Cancer Trials Group	Capacity building support to the Breast Cancer Trials (BCT) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	1/07/2018	1/09/2021	\$1,644,039.10	N	CA 1718 170
Australia and New Zealand Melanoma Trials Group (through Monash University)	2019 Supporting People with Cancer Round 11: Improving Melanoma and Skin Cancer awareness in regional and rural Australia. The Project will develop and deliver patient and consumer centred resources and improve access to quality, coordinated and sustainable melanoma and skin cancer support networks for all Australians.	7/03/2019	30/05/2022	\$132,000.00	N	CA 1718 173
Australian Leukaemia and Lymphoma Group	Capacity building support to the Australasian Leukaemia and Lymphoma Group (ALLG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	1/07/2018	1/09/2021	\$1,650,000.00	N	CA 1718 175
Australian National University	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2016: AUTO-CHECK study: Molecular determinants of autoimmunity and immune related adverse events in advanced cancer patients treated with immune checkpoint inhibitors. APPID: 1130330-Cook	25/04/2017	24/01/2022	\$574,009.00	N	CA 1718 169
Breast Cancer Network Australia	Funding Agreement with BCNA in relation to the Supporting Women in Rural Areas Diagnosed with Breast Cancer Program	11/07/2017	26/10/2021	\$2,616,935.00	N	CA 1718 171
Cancer Council NSW	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2016: Hide and seek with hereditary cancer: Improving detection of colorectal cancer patients with a high risk of Lynch syndrome. APPID: 1123924-Taylor	30/06/2017	29/09/2021	\$579,140.00	N	CA 1718 174
Cancer Council Victoria	Supporting People with Cancer Grant Initiative: Keeping Things on Track	13/06/2017	30/06/2021	\$131,230.00	N	CA 1718 176
CanTeen	Supporting people with cancer Grant initiative - Improving health information and involvement outcomes for adolescent and young adult cancer patients: A Youth Cancer Services system-wide approach	16/03/2018	30/06/2021	\$132,000.00	N	CA 1718 178
Central Adelaide Local Health Network	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Predicting and improving anti-tumour responses to immunotherapy in advanced cancer patients. APPID: 1186306-Ebert	1/06/2020	31/08/2023	\$560,142.00	N	CA 1718 179
Flinders University	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Increasing resilience and reducing smoking for lower socio-economic groups. APPID: 1182598-Ward	1/06/2020	31/08/2023	\$553,820.00	N	CA 1718 180
Flinders University	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Personalising treatment and surveillance for colorectal cancer: prognostication with the circulating tumour-derived methylated DNA markers BCAT1 and IKZF1 AppID: 1161720 - SYMONDS	1/06/2019	31/08/2022	\$553,196.00	N	CA 1718 177
Garvan Institute of Medical Research	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Dual targeting of Src and JAK/STAT3 signalling as a novel personalized treatment strategy for pancreatic cancer APPID: 1143699-Pajic	15/03/2018	14/06/2021	\$300,000.00	N	CA 1718 181
La Trobe University	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) international 2018: Tackling breast cancer heterogeneity for the complete eradication of metastases. AppID: CCR19606878-MERINO	15/05/2019	15/08/2022	\$200,000.00	N	CA 1819 153
La Trobe University	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2015: A multistage multicentre international randomised trial of Conventional care Or Radioablation (stereotactic body radiotherapy) for Extra-cranial oligometastatic disease in lung, breast and prostate cancer (CORE). APPID: 1104569-Foroudi	28/06/2016	31/03/2021	\$430,563.00	N	CA 1718 044
La Trobe University	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Improving Immune Checkpoint Treatment of Colorectal Cancer by STAT3 inhibition APPID: 1144460-Ernst	30/06/2018	29/08/2021	\$598,677.00	N	CA 1718 036
Monash University	Capacity building support to the Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	1/07/2018	1/09/2021	\$1,500,000.00	N	CA 1920 120
Monash University	Capacity building support to the Melanoma and Skin Cancer Trials (MASC; formerly ANZMTG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	1/07/2018	1/09/2021	\$1,500,000.00	N	CA 1920 121
Monash University	Investing in medical Research - fighting childhood cancer: LGG Avastin study	27/10/2017	30/11/2021	\$506,419.00	N	CA 1920 309
Monash University	Investing in medical Research - fighting childhood cancer: AIM BRAIN trial	27/10/2017	31/08/2021	\$1,742,898.00	N	CA 1920 310
Monash University	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Translating Colorectal Cancer Organoids into Patient Care APPID: 1145907-Abud	16/04/2018	15/07/2021	\$597,557.00	N	CA 1920 311
Monash University	2019 Supporting People with Cancer Round 11: Integrated Management of Post Remission Leukaemia to Optimise longevity and Enhance Quality of Life (IMPROVE). This project aims to improve post-remission care for patients treated with acute leukemia.	14/03/2019	30/05/2022	\$120,000.00	N	CA 1920 312
North Metropolitan Health Service	Supporting people with cancer Grant initiative: Adolescent and Young Adult (AYA) Life Now Group Exercise Program	30/03/2017	30/06/2021	\$112,462.00	N	CA 1920 313
Peter MacCallum Cancer Centre	Supporting People with Cancer Grant Initiative:Development of a co-designed, online, supportive care resources for older adults affected by cancer. The "Older and Wiser" project.	1/05/2018	30/03/2021	\$128,700.00	N	CA 1920 314
Queensland University of Technology	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Circulating Tumour Cells: Clinical Application in Head and Neck Cancers. APPID: 1145657-Punyadeera	29/06/2018	28/09/2022	\$599,756.00	N	CA 1920 315
Queensland University of Technology	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Development of a translational bioengineered microenvironment model to advance pre-clinical acute myeloid leukaemia research AppID: 1159637 - BRAY	30/06/2019	29/09/2022	\$133,017.00	N	CA 1920 316
Swinburne University	2019 Supporting People with Cancer Round 11: Australian Carers Talk: An online cancer support resource for carers designed by carers. This Project will deliver an online resource created by carers for carers, integrated into Cancer Council Australia's new national website.	26/02/2019	30/05/2022	\$120,000.00	N	CA 1920 317
Trans Tasman Radiation Oncology Group Limited	Capacity building support to the Trans Tasman Radiation Oncology Group (TROG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	1/07/2018	1/09/2021	\$1,650,000.00	N	CA 1920 318

**Cancer Australia - Contract Listings - Grants**  
**Reporting Period - Calendar Year - 2020**

Trans Tasman Radiation Oncology Group Limited	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Novel Integration of New prostate radiation schedules with adjuvant Androgen deprivation (NINJA) AppID: 1158455-MARTIN	30/06/2019	29/09/2022	\$600,000.00	N	CA 1920 319
University of Adelaide	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Novel co-extinction strategies for treatment of prostate cancer APPID: 1138766-Butler	16/04/2018	29/06/2021	\$596,409.00	N	CA-G1415/51
University of Adelaide	A pharmacodynamic study of the heat shock protein 90 (Hsp90) inhibitor, AUY922, in high-risk, localised prostate cancer Appl ID 1050880	1/05/2013	31/03/2021	\$360,977.00	N	CA-G1516/54
University of Melbourne	Capacity building support to the Australia and New Zealand Sarcoma Association (ANZSA; formerly ASSG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	1/07/2018	1/09/2021	\$1,500,000.00	N	CA-G1718-12
University of Melbourne	Capacity building support to the Primary Care Collaborative Cancer Clinical Trials Group (PC4) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	1/07/2018	1/09/2021	\$1,500,000.00	N	CA-G1718-11
University of Melbourne	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Integrative approaches to identifying the causes of familial breast cancer. APPID: 1188547-Campbell	27/04/2020	26/07/2023	\$547,825.00	N	CA-G1718-32
University of Melbourne	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: The Preclinical Validation of Radio-labelled Girentuximab as a Theranostic Agent in Metastatic Colorectal Cancer. APPID: 1184859-Hollande	23/03/2020	22/06/2023	\$506,210.00	N	CA-G1718-05
University of Melbourne	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: SCRIPT: an RCT of genomic-based stratified colorectal cancer screening in primary care. APPID: 1183338-Emery	30/06/2020	29/09/2023	\$551,184.00	N	CA-G1516/74
University of Melbourne	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019 international: Checkpoint receptors expressed by dendritic cells- do they play a role in immunotherapies? APPID: 20-0300-O'Keefe	1/02/2020	1/05/2023	\$241,027.00	N	CA-G1516/19
University of Melbourne	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: SCORE: Shared care of Colorectal cancer survivors – A randomised controlled trial of hospital-based follow up versus shared hospital / general practice follow up for survivors of colorectal cancer (CRC) AppID: 1158397-JEFFORD	1/04/2019	30/11/2022	\$479,375.00	N	CA-G1516/32
University of Melbourne	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Stereotactic Ablative Radiotherapy (SABR) as a New Precision Treatment Option in Kidney Cancer APPID: 1139464-Siva	30/03/2018	29/06/2021	\$589,082.00	N	CA-G1516/70
University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Application of gene-silencing nanodrugs to inhibit medulloblastoma growth. APPID: 1184840-McCarroll	26/02/2020	25/05/2023	\$298,554.00	N	CA 1819 103
University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Functional precision medicine for aggressive childhood cancers. APPID: 1185313-Kavallaris	1/10/2020	30/12/2023	\$596,955.00	N	CA 1819 104
University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Decoding the Dark Matter of the High-Risk Paediatric Cancer Genome AppID: 1165556-COWLEY	7/05/2019	6/08/2022	\$377,048.00	N	CA 1819 107
University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Targeting Polo-like kinase 1 as a novel therapeutic opportunity for Diffuse Intrinsic Pontine Gliomas AppID: 1165708-ZIEGLER	28/05/2019	27/02/2023	\$278,281.00	N	CA 1819 109
University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Targeting the NAD pathway as a new therapeutic strategy for high-risk leukaemia in children AppID: 1164865-HENDERSON	20/05/2019	19/08/2022	\$321,045.00	N	CA 1819 110
University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS)2018: Therapeutic targeting of a novel self-renewal signalling in leukaemia stem cells AppID: 1165516-WANG	30/06/2019	31/03/2023	\$300,000.00	N	CA 1819 111
University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Microtubule deregulation in lung cancer and therapeutic strategies APPID: 1141485-Kavallaris	29/03/2018	28/06/2021	\$592,694.00	N	CA 1819 112
University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: The contribution of rare alleles to non high grade serous ovarian cancer APPID: 1147276-Ramus	30/06/2018	29/08/2021	\$597,632.00	N	CA 1819 113
University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2016: Reprogramming the Tumour Microenvironment with the use of Nanomedicines for the Treatment of Pancreatic Cancer. APPID: 1126736-Phillips	30/06/2017	31/03/2021	\$247,983.25	N	CA 1819 115
University of New South Wales	2019 Supporting People with Cancer Round 11: Co-designing patient engagement strategies to enhance safety in cancer services for culturally and linguistically diverse (CALD) people	21/05/2019	30/05/2022	\$119,660.25	N	CA 1819 116
University of Newcastle	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Obesity epidemic fuelling the surge of endometrial cancers: Elucidating the role and targeting of molecular signals involved in fat and endometrial cancer cross-talk. APPID: 1187542-Tanwar	31/03/2020	28/05/2023	\$600,000.00	N	CA 1819 117
University of Queensland	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Streamlining lung cancer diagnosis through genomic testing of cytology smears APPID: 1147067-Fielding	30/06/2018	30/09/2022	\$400,000.00	N	CA 1819 118
University of Queensland	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Exploiting CDK4/6 inhibition to treat medulloblastoma AppID: 1165777-WAINWRIGHT	30/06/2019	29/09/2022	\$196,206.00	N	CA 1819 122
University of Queensland	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Development of oxytocin receptor specific tracers for improved breast cancer management APPID: 1146504-Alewood	30/06/2018	29/08/2021	\$400,000.00	N	CA 1819 123
University of Sydney	Capacity building support to the Australasian Leukaemia and Lymphoma Group (AGITG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	1/07/2018	1/09/2021	\$1,500,000.00	N	CA 1819 137
University of Sydney	Capacity building support to the Australasian Lung Cancer Trials Group (ALTG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	1/07/2018	1/09/2021	\$1,500,000.00	N	CA 1819 146
University of Sydney	Capacity building support to the Australia New Zealand Gynaecological Oncology Group (ANZGOG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	1/07/2018	1/09/2021	\$1,500,000.00	N	CA 1819 182
University of Sydney	Capacity building support to the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	1/07/2018	1/09/2021	\$1,500,000.00	N	CA-G1718-06

**Cancer Australia - Contract Listings - Grants**  
**Reporting Period - Calendar Year - 2020**

University of Sydney	Capacity building support to the Cooperative Trials Group for Neuro-Oncology (COGNO) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	1/07/2018	1/09/2021	\$1,500,000.00	N	CA-G1718-07
University of Sydney	Capacity building support to the Psycho-oncology Co-operative Research Group (PoCoG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	1/07/2018	1/09/2021	\$1,477,995.00	N	CA-G1718-08
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Personalised targeted therapy for adolescent and young adult medulloblastoma patients AppID: 1165910-HOVEY	30/06/2019	29/09/2022	\$167,168.50	N	CA-G1718-09
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: P3BEP Trial: Accelerating First-Line Chemotherapy to Improve Cure Rates for Advanced Germ Cell Tumours: An Australian-Led, International Randomised Trial. AppID: 1159837-GRIMISON	30/06/2019	29/09/2022	\$600,000.00	N	CA-G1718-10
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: The ECHO trial: Exercise during Chemotherapy for Ovarian cancer AppID: 1158566-HAYES	14/05/2019	13/08/2022	\$597,443.00	N	CA-G1718-33
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Improving tumour targeting and delineation in lung cancer radiotherapy AppID: 1161748-O'Brien	30/06/2019	29/09/2023	\$600,000.00	N	CA-G1718-31
University of Sydney	2019 Supporting People with Cancer Round 11 - Aboriginal people with cancer to access evidence based care: developing a manual and training package in use for workers in primary care to support cancer care	30/05/2019	30/05/2022	\$120,000.00	N	CA-G1718-14
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: ASCOLT: ASpirin for Dukes C and high risk B COLorecTal cancer. An International, Multi-centre, Double Blind, Randomised Trial. APPID: 1182824-Segelov	13/05/2020	12/08/2023	\$465,000.00	N	CA-G1718-15
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Remove the Mask: Reducing Anxiety and Distress for Head and Neck Cancer Radiotherapy Patients. APPID: 1180776-Keall	30/06/2020	29/09/2023	\$568,445.00	N	CA-G1718-30
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Life and Health After Childhood Cancer: a national data linkage cohort study. APPID: 1187545-Nassar	1/06/2020	31/08/2023	\$569,900.00	N	CA-G1718-16
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2014: ANZMTG 02.12 RADICAL - RADIotherapy (RT) or Imiquimod (ImiQ) in Complex lentigo maLigna (LM). APPID: 1083221-Guitera	1/05/2015	31/12/2021	\$600,000.00	N	CA-G1516/69
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Empowering the clinician-patient-carer trio: RCT of novel online education modules to facilitate effective family carer involvement in oncology. APPID: 1146383-Juraskova	19/03/2018	18/03/2023	\$296,601.00	N	CA-G1516/55
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2015: Developing a Patient-Reported Symptom Index for Non-muscle Invasive Bladder Cancer. APPID: 1103036-Patel	30/06/2016	30/09/2021	\$233,158.50	N	CA-G1516/85
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: The Liver Ablative Radiotherapy with KIM (LARK) Clinical Trial APPID:1143778-Keall	1/05/2018	30/07/2021	\$583,371.00	N	CA-G1516/37
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Molecular drivers of malignancy and response to targeted treatment in chemotherapy-resistant low-grade serous ovarian cancer APPID: 1142697-de Fazio	19/03/2018	18/06/2021	\$492,411.00	N	CA-G1516/34
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2016: High Precision Radiotherapy: Dual Cardiac and Respiratory Motion Management. APPID: 1123068-O'Brien	30/06/2017	29/09/2021	\$597,325.50	N	CA-G1516/24
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2016: The SPAR Trial: a randomised placebo-controlled phase 2 trial of simvastatin with preoperative chemoradiation for rectal cancer. APPID: 1125958-Ackland	30/06/2017	31/03/2023	\$148,857.00	N	CA 1415 017
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2015: The PEARL trial: Palliative care Early in Advanced Lung cancers. APPID: 1101882-Mileshkin	18/04/2016	30/09/2021	\$598,099.00	N	CA-A 1213/28
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2015: ICON9: A phase 3 randomised trial of cediranib and olaparib maintenance in patients with relapsed platinum sensitive ovarian cancer. APPID: 1100619-Mileshkin	15/04/2016	31/03/2022	\$600,000.00	N	CA 1819 126
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2015: Phase II randomised placebo-controlled, double blind, multisite study of acetazolamide versus placebo for management of cerebral oedema in recurrent and/or progressive HGG requiring treatment with dexamethasone – The ACED trial. APPID: 1098932-Agar	1/04/2016	30/03/2022	\$524,365.00	N	CA 1819 126
University of Technology Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2016: Randomised, double-blind, placebo-controlled phase III trial of oral melatonin for the prevention of delirium in hospital in people with advanced cancer. APPID: 1127727-Agar	1/04/2017	31/03/2021	\$599,820.00	N	CA 1819 126
University of Western Australia	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Intraoperative immunotherapy to prevent relapse in soft tissue sarcoma. APPID: 1184331-Lesterhuis	1/04/2020	30/06/2022	\$197,525.00	N	CA 1819 171
University of Western Australia	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Measuring breast density in younger women to inform primary prevention and early detection of breast cancer. APPID: 1147677-Stone	8/03/2018	31/03/2022	\$592,636.00	N	CA 1819 181
University of Western Australia	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Mixed radiotherapy fractionation: modulating tumour microenvironment to stimulate and enhance immunotherapy AppID: 1163065-EBERT	1/05/2019	30/07/2022	\$597,521.00	N	CA-G1718-35
University of Western Australia	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Sensitising medulloblastoma to conventional treatment using kinase inhibitors APPID: 1147153-Gottardo	1/05/2018	31/07/2021	\$530,428.00	N	CA-G1718-29
Walter and Eliza Hall Institute of Medical Research	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Targeting BCL-2 in estrogen receptor positive breast cancer AppID: 1165878-LINDEMAN	29/04/2019	28/07/2022	\$599,562.00	N	CA-G1617/80
Walter and Eliza Hall Institute of Medical Research	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Targeting multidrug resistance protein 1 (MDR1) enhances the efficacy of Smac-mimetic-based therapy in Acute Myeloid Leukaemia AppID: 1162023-BRUMATTI	1/06/2019	31/08/2022	\$361,023.00	N	CA-G1617/88

**Cancer Australia - Contract Listings - Grants**  
**Reporting Period - Calendar Year - 2020**

Walter and Eliza Hall Institute of Medical Research	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Designing Chimeric Antigen Receptor T cells for Diffuse Intrinsic Pontine Glioma AppID: 1164657-JENKINS	6/05/2019	5/08/2022	\$592,388.00	N	CA-G1718-34
---	---	-----------	-----------	--------------	---	-------------